Project Grant R21AG087888
- This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), is focused on investigating the association between the Alzheimer's disease (AD) risk gene APOE4 and the menopause-related hormone follicle-stimulating hormone (FSH) in the initiation and progression of AD, particularly in women. The $564,530 award to Emory University will support research to explore how APOE4 may facilitate AD pathology in women by interacting with FSH-induced...
- This $3.5 million project grant from the National Institutes of Health's National Institute on Aging will fund research into sex differences related to epigenetic parent-of-origin effects and Alzheimer's disease. The Regents of the University of California, San Francisco will investigate how the maternal versus paternal X chromosome impacts neural vulnerability to Alzheimer's-related deficits in mouse models and primary neurons. The researchers hypothesize that imprinting or silencing of genes...
- This Project Grant award of $431,750 from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research to investigate the interaction between biological sex and APOE genotype in modulating Alzheimer's disease (AD) risk. The research will leverage human induced pluripotent stem cell lines with various APOE genotypes and sex chromosome complements to examine how APOE and sex influence amyloid-beta processing, tau hyperphosphorylation, and transcriptional changes...
- The University of North Carolina at Chapel Hill (UNC-CH) received a $427,625 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) to develop and validate a computational framework for identifying excitation-inhibition imbalances in Alzheimer's disease (AD) using multi-modal neuroimaging data. The goal is to create an innovative technique that can noninvasively detect circuit-level disruptions in brain networks associated with AD pathology, which...
- This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $1,853,477 to the Research Foundation for Mental Hygiene, Inc. (RFMH) at the Nathan S. Kline Institute to conduct research on hyperexcitability and interictal spike activity in Alzheimer's disease. The research aims to investigate the origins and mechanisms of these neural phenomena, as well as evaluate whether selectively inhibiting them can improve cognition and reduce...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $398,046 to the Palo Alto Veterans Institute for Research (Pavir) to systematically test the combined effects of anti-amyloid treatment and brain stimulation in a mouse model of Alzheimer's disease. The research aims to assess the biochemical response, as well as memory and electrocorticography (ECoG) improvements, from the combination of these two therapeutic approaches. The project will...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $851,002 to Arizona State University (ASU) to systematically investigate the genetic contributions of sex chromosomes to Alzheimer's disease (AD). The project will apply a sex-chromosome-aware alignment approach to re-analyze Next-Generation Sequencing (NGS) data from large AD clinical cohorts. Variant calling and gene expression analyses will be performed to assess how genetic factors on the...
- This federal Project Grant award of $815,215 was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to Yale University. The funding supports a multimodal neuroimaging study to understand sex-based differences in brain circuitry and Alzheimer's disease (AD) pathology. The project leverages new and existing datasets to evaluate the impact of sex and sex-based factors, such as reproductive period and APOE genotype, on functional brain networks and tau...
- This $3.61 million project grant from the National Institutes of Health's National Institute on Aging will fund research from July 2022 to June 2025 aimed at understanding and addressing neurovascular coupling dysfunction in Alzheimer's disease and Alzheimer's disease-related dementias. Specifically, the University of Colorado Denver will investigate the hypothesis that restoring neurovascular coupling can mitigate synaptic plasticity deterioration in the hippocampus and its behavioral...
- This $244,023 Project Grant was awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to The Trustees of Columbia University in the City of New York to conduct research on the social mechanisms underlying sex differences in Alzheimer's disease (AD). The research project aims to determine whether contextual factors influence sex differences in AD outcomes, evaluating how exposure to societal barriers interacts with cognitive and brain resilience to AD pathology and...
CONNECTING NEURONAL HYPEREXCITABILITY AND SEX DIFFERENCES IN ALZHEIMER'S DISEASE (AD) USING BIOPHYSICALLY-INFORMED IN-SILICO BRAIN SIMULATIONS AND EXPERIMENTAL DATA FROM MOUSE MODELS OF AD - THE MECHANISM UNDERLYING NEURONAL HYPEREXCITABILITY, AS A RESULT OF EXCITATION-INHIBITION (E-I) IMBALANCE, LEADING TO COGNITIVE DETERIORATION IN ALZHEIMER'S DISEASE (AD) IS NOT FULLY UNDERSTOOD AND EFFECTIVE APPROACHES TO PREVENT OR REVERSE MEMORY DEFICITS ARE UNAVAILABLE. OUR MULTIMODAL MRI CONNECTOMICS DEMONSTRATED A HYPEREXCITATION CONNECTOME PHENOTYPE IN HEALTHY WOMEN APOE4 CARRIERS AS THEY AGE, RAISING THE POSSIBILITY THAT AT LEAST SOME SEX DIFFERENCES IN AD MAY BE EXPLAINED BY E4 FEMALE CARRIER-SPECIFIC NEURONAL HYPEREXCITATION. IN SUPPORT OF THIS, RESTING STATE FUNCTIONAL MAGNETIC RESONANCE IMAGING (RS-FMRI) IN APPNL-G-F/NL-G-F REVEALED HIGHER INTERHEMISPHERIC FUNCTIONAL CONNECTIVITY IN THE HIPPOCAMPUS OF FEMALE MID-LIFE MICE. FURTHER, WE OBSERVED REDUCED FUNCTIONAL ANISOTROPY, ALTERED MYELIN AND OLIGODENDROCYTE COUNT, AND IMPORTANTLY, ALTERED TRANSCRIPTION PHENOTYPE OF EXCITATORY AND INHIBITORY NEURONS IN THE HIPPOCAMPUS OF THESE FEMALE MICE. THE ANTISEIZURE DRUG LEVETIRACETAM (LEV) IS CURRENTLY BEING TESTED IN HUMAN TRIALS, WITH EARLY DATA SUGGESTING THAT IT DOES IMPROVE COGNITION IN THOSE WITH SIGNS OF HYPEREXCITABILITY. HOWEVER, THERE IS CONFLICTING INFORMATION CONCERNING THE EFFICACY OF THE DRUG AND ITS MECHANISM IS NOT FULLY UNDERSTOOD. THIS COLLABORATIVE, MULTIDISCIPLINARY MPI PROGRAM IS AIMED AT UNRAVELING THE EFFICACY OF LEV IN HUMANS AND MOUSE MODELS BY LEVERAGING EXPERTISE IN COMPUTATIONAL AND EXPERIMENTAL NEUROSCIENCE. WE WILL TEST THE HYPOTHESIS THAT HYPEREXCITABILITY IS MORE PREVALENT BOTH IN APOE4 WOMAN CARRIERS AND IN FEMALE FAD-LINKED APPNL-G-F/NL-G-F AND LOAD-LINKED APOE4 KNOCKIN MICE AND THAT LEV TREATMENT WILL NORMALIZE HYPEREXCITABILITY AND COGNITIVE DEFICITS IN A SEX-DEPENDENT MANNER. IN THE R21 PHASE, THE EXPERIMENTAL APPROACH WILL ESTABLISH FEASIBILITY OF LEV TREATMENT IN APPNL-G-F/NL-G-F FEMALE MICE. THE COMPUTATIONAL APPROACH WILL DEVELOP NEW BIOPHYSICALLY - INFORMED COMPUTATIONAL FRAMEWORK FOR MODELING EXPERIMENTAL MOUSE DATA. IN THE R33 PHASE, WE WILL ESTABLISH THE EFFECT OF LEV ON HYPEREXCITABILITY AND PATHOLOGY IN ASSOCIATION WITH SEX, APOE4 AND AMYLOIDOSIS, AND GENERALIZE OUR COMPUTATIONAL APPROACHES FROM MOUSE HIPPOCAMPUS TO THE ENTIRE BRAIN TO CHARACTERIZE THE WHOLE-BRAIN BIOPHYSICAL PARAMETERS OF E-I BALANCE IN AD WITH OR WITHOUT LEV TREATMENT. THE RESULTS OF THIS PROGRAM WILL PROVIDE NOVEL INSIGHT INTO THE MOLECULAR MECHANISM OF E-I AND LEV, AND ITS THERAPEUTIC VALUE IN AD.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $185.4k | 8/18/25 | ||
| Not listed | $658 | 9/10/24 | ||
| Not listed | $248.8k | 9/6/24 |